Scientists Find Gene Behind Preeclampsia Deaths

A chance hallway conversation between a dermatologist and an obstetrician just unlocked what could be the key to ending preeclampsia, a pregnancy complication that kills thousands of mothers and babies each year.

Dr. Johann Gudjonsson was studying why women develop more autoimmune diseases when a colleague mentioned something curious. Doctors often struggle to tell the difference between autoimmune disorders and preeclampsia because the symptoms look so similar.

That moment changed everything. Gudjonsson wondered if his team had already found the answer while studying women's skin.

Preeclampsia affects up to 8% of pregnancies worldwide and has no cure. Women experience dangerously high blood pressure, headaches, and confusion, but many don't show symptoms until it's too late. The only current treatment is early delivery, which can put both mother and baby at risk.

For decades, doctors knew the problem started in the placenta but couldn't figure out why. Gudjonsson's team discovered that a gene called VGLL3, which is highly active in both women's skin and the placenta, appears to be the root cause.

The gene controls special cells called trophoblasts that help the placenta grow and connect to the mother's blood vessels. When VGLL3 goes haywire, these cells malfunction and trigger the cascade of symptoms that define preeclampsia.

The research team included scientists who had personally survived preeclampsia. Dr. Ashley Bartell, who experienced two preeclamptic pregnancies, says the discovery hits close to home. Even as an expert, she struggled to know if her son truly needed to be born five weeks early.

Why This Inspires

This breakthrough came from scientists who refused to stay in their lanes. A dermatologist saw a problem outside his specialty and decided to chase it anyway, hiring experts in pregnancy and immunology to join forces.

The discovery opens three major doors: better diagnostic tests to catch preeclampsia earlier, targeted treatments to manage it during pregnancy, and potentially a way to prevent it entirely. Researchers can now design therapies that specifically target VGLL3 instead of just managing symptoms.

Dr. Paige Porrett, a uterus transplant surgeon not involved in the study, says this kind of cross-discipline collaboration is exactly how medicine solves its toughest mysteries. When experts from different fields connect the dots, impossible problems suddenly have answers.

For the millions of women who will become pregnant this year, this research represents genuine hope that preeclampsia could become a preventable condition rather than a terrifying uncertainty.